Inkef

Huge congratulations to Siete Hamminga and the entire Robin Radar Systems team for joining forces with Parcom for the next phase of growth! 🚀   At Inkef, we choose patience over fast exits. We strongly believe that true value and sustainable returns can only be created with a long-term strategic vision. This strategy has paid off.    We are extremely proud of what Siete and his team have achieved over the years and are honoured to have been part of this incredible journey since the early days.   Onwards and upwards for Robin Radar! https://lnkd.in/e5Hhdrn2

🚀 Exciting News! 🚀 We are thrilled to announce that our portfolio company, iOnctura, has closed a EUR 80 million Series B round! Led by Syncona Limited and the European Investment Council, this funding will drive the late-stage development of treatments for hard-to-treat cancers. Since our initial investment in 2019, iOnctura's team has delivered exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat, in rare tumors with high unmet needs. With this new financing, roginolisib will be tested in broader trials for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis, while cambritaxestat will advance for fibrotic cancers like metastatic pancreatic cancer. We are excited to welcome new investors and continue supporting iOnctura as it brings these critical treatments closer to patients in need. #Biotech #Investment #CancerTreatment #Pharma #Innovation #HealthTech #SeriesBRound #iOnctura #EuropeanInvestmentCouncil #Inkef

Great news: QurAlis has signed a licensing deal with Eli Lilly for their UNC13A program. Congratulations to Kasper Roet and his team for their outstanding work in advancing new therapeutic options for ALS patients! https://lnkd.in/ekhv2Syu

Huge congratulations to our portfolio company Provable Markets for raising their Series A round - welcome on board Dialectic Capital Management. Well done Matthew Cohen and team. We’re excited to continue this journey with you! 🚀🚀🚀 cc Corne Jansen Carien Nantois-Beijer Provable Labs

We are excited to announce that our portfolio company Cardior Pharmaceuticals will be acquired by Novo Nordisk for up to 1.025 billion Euros! The acquisition will support the accelerated clinical development of Cardior’s lead compound CDR132L, currently in a Phase 2 trial in heart failure.   At Inkef it is our goal to build companies and foster the next big ideas in healthcare from their origins in the Netherlands and Europe into the world. Inkef led Cardior’s Series B financing round in 2021 and has actively supported the company in its journey to become a leader in the cardiovascular space ever since. We saw the tremendous potential of Cardior’s therapeutic approach early on to truly address the root causes of cardiac dysfunctions. Heart disease is the most common cause of death worldwide and there is a significant unmet need for new and effective treatments. CDR132L could become a first-in-class therapy for heart failure, which affects more than 65 million people globally, and achieve lasting positive therapeutic impact for patients.   Inkef is proud to see Cardior progress in its quest to change the treatment paradigm for heart disease by joining forces with a global leader like Novo Nordisk. This acquisition validates Inkef’s investment philosophy: make bold bets backed by strong data in fields that are mature for a truly novel approach.   “When we looked at Cardior we were impressed by their ambition and the data they had to back it. - Said Simone Botti, Senior Partner and Head of Healthcare at Inkef – “As a venture capitalist you cannot miss the opportunity to back a company that has a real chance to develop a truly disease-modifying therapy in heart failure. We are enthused to see that Novo sees the same potential in Cardior as we did when we led their Series B financing”   A big thank you to the Cardior team, Dr. Claudia Ulbrich, Thomas Thum Peter Ruile, and all co-investors Bristol Myers Squibb, BioMedPartners, HTGF | High-Tech Gründerfonds, FundPlus, Sunstone Life Science Ventures, Hadean Ventures, coparion and EQT Life Sciences; all Inkef members past and present who made this success possible and YPOG for supporting us in this transaction. https://lnkd.in/eASMFJxv

We are excited to announce that our portfolio company ONWARD Medical has successfully raised €20 million in a capital raise through an accelerated bookbuild offering and a public offering in France. INKEF is proud to see ONWARD medical progress in its journey to restore movement, function and independence in people with spinal cord injury (SCI) and movement disorders. As the company’s largest investor and one of its earliest backers we will continue to support one of the best examples of our investment philosophy: make bold bets backed by strong data in fields that are mature for a truly novel approach. Congratulations to Dave Marver and the ONWARD Medical team!

Inkef is pleased to announce that our Dutch portfolio company Calypso Biotech will be acquired by Novartis for up to USD 425M of which USD 250M upfront. Novartis will add Calypso Biotech’s potential best-in-class anti-IL-15 monoclonal antibody to its Immunology pipeline and explore it across a wide variety of autoimmune indications with high unmet medical need. Inkef acted as co-lead investor from Series A through to trade sale. A big thanks to the Calypso Biotech team: Alain Vicari, Nicolas Guyon-Gellin, M.D., MSc and Jos G.A. Houbiers and all co-investors Arthur Franken Tristan Maguet at Gilde Healthcare, Ena P. at Fountain Healthcare Partners, Cheryl Zimberlin, Noga Yerushalmi, Charlotte Kremers at M Ventures and Fiona MacLaughlin at Johnson & Johnson. https://lnkd.in/eQ2uKmRe